Administration of miglitol until 30 min after the start of a meal is effective in type 2 diabetic patients

Diabetes Research and Clinical Practice

Volumn 78, Issue 1, 2007, Pages 30-33

  Aoki, Kazutaka ^a   Nakamura, Akinobu ^a   Ito, Satoshi ^a   Nezu, Uru ^a   Iwasaki, Tomoyuki ^a   Takahashi, Mayumi ^a   Kimura, Mari ^a   Terauchi, Yasuo ^a  

^a YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

GI; Miglitol; Postprandial glucose; Type 2 diabetes

Indexed keywords

GLUCOSE; INSULIN; MIGLITOL; VOGLIBOSE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; HUMAN; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS;

1-DEOXYNOJIRIMYCIN; ALPHA-GLUCOSIDASES; BLOOD GLUCOSE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; IMINO PYRANOSES; INSULIN; MALE; MIDDLE AGED;

EID: 34548299976     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2007.01.072     Document Type: Article

References (17)

1. Chiasson J.L., et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 15 (2002) 2072-2077
2. The DECODE Study Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 354 (1999) 617-621
3. DECODA Study Group. Cardiovascular risk profile assessment in glucose-intolerant Asian individuals-an evaluation of the World Health Organization two-step strategy: the DECODA Study (Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Asia). Diabetic Med. 19 (2002) 549-557
4. Tominaga M., Eguchi H., Manaka H., Igarashi K., Kato T., and Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 22 (1999) 920-924
5. Baron A.D. Postprandial hyperglycaemia and alpha-glucosidase inhibitors. Diabetes Res. Clin. Pract. 40 Suppl. (1998) S51-S55
6. American Diabetes Association. Standards of medical care in diabetes-2006. Diabetes Care 29 (2006) S4-S42
7. Yamasaki Y., Katakami N., Hayaishi-Okano R., Matsuhisa M., Kajimoto Y., Kosugi K., et al. α-Glucosidase inhibitor reduces the progression of carotid intima-media thickness. Diabetes Res. Clin. Pract. 67 (2005) 204-210
8. Josse R.G., Chiasson J.L., Ryan E.A., Lau D.C., Ross S.A., Yale J.F., et al. Acarbose in the treatment of elderly patients with type 2 diabetes. Diabetes Res. Clin. Pract. 59 (2003) 37-42
9. Hertz R.P., Unger A.N., and Lustik M.B. Adherence with pharmacotherapy for type 2 diabetes: a retrospective cohojt study of adults with employer-sponsored health insurance. Clin. Ther. 27 (2005) 1064-1073
10. Holman R.R., Cull C.A., and Turner R.C. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44). Diabetes Care 22 (1999) 960-964
11. Kawamori R., Toyota R., Oka Y., Yamada N., Iwamoto Y., Tajima N., et al. Improvement of glycemic control following 12-week treatment with miglitol in Japanese type 2 diabetes: a double-blind, randomized, placebo- and voglibose-controlled trial (Abstract). Diabetes Metab 29 Hors Série 2 (2003) 4S263
12. Scott L.J., and Spencer C.M. Miglitol. A review of its therapeutic potential in type 2 diabetes mellitus. Drugs 59 (2000) 521-549
13. Schnack C., Roggla C., Luger A., and Schernthaner G. Effects of the alpha-glucosidase inhibitor 1 desoxynojirimycin (Bay m 1099) on postprandial blood glucose, serum insulin and C-peptide levels in type II diabetic patients. Eur. J. Clin. Pharmacol. 30 (1986) 417-419
14. Johnston P.S., Lebovitz H.E., Coniff R.F., Simonson D.C., Raskin P., and Munera C.L. Advantages of alpha-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients. J. Clin. Endocrinol. Metab. 83 (1998) 1515-1522
15. Johnston P.S., Coniff R.F., Hoogwerf B.J., Santiago J.V., Pi-Sunyer F.X., and Krol A. Effects of the carbohydrase inhibitor miglitol in sulfonylurea-treated NIDDM patients. Diabetes Care 17 (1994) 20-29
16. Rosak C., Nitzsche G., Konig P., and Hofmann U. The effect of the timing and the administration of acarbose on postprandial hyperglycaemia. Diabetic Med. 12 (1995) 979-984
17. Asakura T., Seino H., Nozaki S., Suzuki Y., and Abe R. Effect of acarbose taken just before and after a meal on plasma glucose level in Japanese healthy subjects. Jpn. J. Hosp. Pharm. 25 (1999) 715-720